Nai-Kong V. Cheung

Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.

Association of CYP3A4 genotype with treatment-related leukemia.

Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.

Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.

Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma.

Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.

Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma.

Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6.

Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.

Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.

Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.

Chronic neuroblastoma.

Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.

Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.

Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins.

Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.

Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.

Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification.

Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy.

Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis.

Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.

Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.

Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.

Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.

Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Treatment of spinal involvement in neuroblastoma patients.

The impact of gross total resection on local control and survival in high-risk neuroblastoma.

Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.

Treatment reduction for neuroblastoma.

Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.

Antibody-based targeted radiation to pediatric tumors.

Long-term complications in survivors of advanced stage neuroblastoma.

Characteristics of stem cells from human neuroblastoma cell lines and in tumors.

Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan.

Prognostic value of MYCN and ID2 overexpression in neuroblastoma.

Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.

Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9.

Neuroblastoma--from genetic profiles to clinical challenge.

High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.

Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.

Exploiting the MIBG-avidity of neuroblastoma for staging and treatment.

FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.

What factors predict a favorable outcome in young children with disseminated neuroblastoma?

Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

Disialoganglioside directed immunotherapy of neuroblastoma.

Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.

Induction for high-risk neuroblastoma.

Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility.

Brain-sparing radiotherapy for neuroblastoma skull metastases.

Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy.

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

Novel markers of subclinical disease for Ewing family tumors from gene expression profiling.

Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome.

Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.

Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography.

Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Management and outcome of stage 3 neuroblastoma.

Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs.

Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.

Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma.

Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.

Monoclonal antibody therapies for solid tumors.

Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.

Immunotherapy of Childhood Sarcomas.

Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer.

MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.

A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.

Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody.

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma.

Neuroblastoma: Therapeutic strategies for a clinical enigma.

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.

Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections.

High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma.

Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid.

High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.

Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.

Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries.

Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.

Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma.

MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.

Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.

Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma.

Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.

In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors.

Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma.

Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases.

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.

Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.

Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis.

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2.

Antibody induced pain in children: An opportunity to study pain mechanism, IgG design and analgesics.

When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?

GD2-targeted immunotherapy and radioimmunotherapy.

Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Disialoganglioside GD2 as a therapeutic target for human diseases.

Osteochondroma in long-term survivors of high-risk neuroblastoma.

Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.

Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.

A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.

Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy.

Radioimmunotherapy of human tumours.

Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G immunotherapy and isotretinoin: a prospective Phase II study.

A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.

Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.

Generation of TCR-Like Antibodies Using Phage Display.

Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.

Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering.

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.

Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Temporal stability and molecular persistence of the bone marrow plasma cell antibody repertoire.

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.

Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.

Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

A phase II study of radioimmunotherapy with intraventricular I-3F8 for medulloblastoma.

Erratum to 'Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies' [Cancer Treat. Rev. 58C (2017) 22-33].

Targeting Intracellular Antigens with pMHC-Binding Antibodies: A Phage Display Approach.

Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G immunotherapy.

Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.

Dose-escalation is needed for gross disease in high-risk neuroblastoma.

Treatment and outcome of adult-onset neuroblastoma.

A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.

Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.

Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.

Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.

Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.

Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.

Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma.

Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.

Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency.

ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.

An -Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy.

Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.

Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.

Targets and Antibody Formats for Immunotherapy of Neuroblastoma.

Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma.

A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy.

IntraOmmaya compartmental radioimmunotherapy using I-omburtamab-pharmacokinetic modeling to optimize therapeutic index.

Alpha radioimmunotherapy using Ac-proteus-DOTA for solid tumors - safety at curative doses.

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.

Cancer immunotherapy via targeted TGF-β signalling blockade in T cells.

B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy.

A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy.

Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.

Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.

Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM.

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.

KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.

Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3 NK Cell Subset with a Bcl11b-Regulated T Cell Signature.

Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.

Reciprocal impacts of telomerase activity and ADRN/MES differentiation state in neuroblastoma tumor biology.

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor.

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma.

Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins.

Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia.

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.

Bispecific antibodies for the treatment of neuroblastoma.

Immunotherapy with anti-G monoclonal antibody in infants with high-risk neuroblastoma.

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells.

Pretargeting: A Path Forward for Radioimmunotherapy.

Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma.

Phase 1 study of intraventricular I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.

Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein.

Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease.

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.

Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors.

Clonal evolution during metastatic spread in high-risk neuroblastoma.